Meeting
2013 ASCO Annual Meeting
A phase I, dose-escalation trial of continuous and pulsed-dose afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: Final analysis.
Authors
Quincy S. Chu
Cross Cancer Centre, Edmonton, AB, Canada
Quincy S. Chu , Randeep S. Sangha , Sebastien J Hotte , Gwen Sergenson , Vikram K. Chand , Roxana Sufan , Yu Gu , David Schnell , Hal W. Hirte
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Cytotoxic and Other Novel Agents
Clinical Trial Registration Number
NCT01169675
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2523)
DOI
10.1200/jco.2013.31.15_suppl.2523
Abstract #
2523
Poster Bd #
11
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A call for global harmonization of phase I oncology trials: Results from two parallel, first-in-human phase I studies of DS-7423, an oral PI3K/mTOR dual inhibitor in advanced solid tumors conducted in the United States and Japan.
First Author: Tomoya Yokota
Poster
2017 ASCO Annual Meeting
First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in advanced solid tumors.
First Author: Noriko Yanagitani
Poster
2015 ASCO Annual Meeting
First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M.
First Author: Daniel Shao-Weng Tan
Poster
2013 ASCO Annual Meeting
Safety and efficacy of nintedanib (BIBF 1120) plus pemetrexed in Japanese patients with advanced or recurrent non-small cell lung cancer (NSCLC): A phase I study.
First Author: Haruko Daga